{
    "clinical_study": {
        "@rank": "57095", 
        "arm_group": {
            "arm_group_label": "Ha44 Gel 0.74% w/w", 
            "arm_group_type": "Experimental", 
            "description": "Open label, one arm"
        }, 
        "brief_summary": {
            "textblock": "The primary purpose of the study is to evaluate safety and tolerability of a single\n      application of Ha44 Gel 0.74% w/w for the treatment of head lice. Secondary purpose is to\n      evaluate PK of Ha44  and benzyl alcohol under conditions of maximal exposure in pediatric\n      population."
        }, 
        "brief_title": "A Pediatric Safety and Pharmacokinetics Study of Ha44 Gel Administered Topically for Treatment of Head Lice Infestation", 
        "condition": "Head Lice Infestation", 
        "condition_browse": {
            "mesh_term": [
                "Parasitic Diseases", 
                "Mite Infestations", 
                "Lice Infestations"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Male or female, 6months < 3years of age\n\n          2. Good health\n\n          3. Active head lice infestation defined as the presence of at least 3 live lice\n\n          4. Dermatological condition of scalp (at least G2 erythema or pruritus with evidence of\n             excoriation/inflammation)\n\n          5. Parent/guardian agrees to allow PK samples collected\n\n          6. Signed Informed Consent Form\n\n        Exclusion Criteria:\n\n          1. Condition or illness that in the opinion of the investigator may interfere with the\n             study results.\n\n          2. Current dermatological disease that may compromise the health of subject or the\n             assessment of safety. Subjects with scalp ulceration or evidence of scalp infection\n             should not be enrolled.\n\n          3. Prior reaction to product containing piperonyl butoxide, pyrethrin, or pyrethrum\n             extract.\n\n          4. Receiving systemic or topical medication that may interfere the study results.\n\n          5. Received an investigational agent within 30 days prior to Day 0."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "2 Years", 
            "minimum_age": "6 Months"
        }, 
        "enrollment": {
            "#text": "22", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 9, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02010333", 
            "org_study_id": "Ha03-003"
        }, 
        "intervention": {
            "arm_group_label": "Ha44 Gel 0.74% w/w", 
            "intervention_name": "Ha44 Gel 0.74% w/w", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "December 9, 2013", 
        "location": [
            {
                "contact": {
                    "last_name": "David Cardona, MD", 
                    "phone": "559-595-1861"
                }, 
                "facility": {
                    "address": {
                        "city": "Dinuba", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "93618"
                    }, 
                    "name": "Universal Biopharma Research Institute"
                }, 
                "investigator": {
                    "last_name": "David Cardona, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Lydie Hazan", 
                    "phone": "310-289-8242"
                }, 
                "facility": {
                    "address": {
                        "city": "Los Angeles", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "90036"
                    }, 
                    "name": "Axis Clinical Trials"
                }, 
                "investigator": {
                    "last_name": "Lydie Hazan, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Clinically significant changes in Physical Examinations, vital signs, safety laboratory tests and assessments of scalp and eye irritation and Electrocardiogram. The frequency and severity of Adverse Events.", 
            "measure": "Safety and tolerability of Ha44 Gel", 
            "safety_issue": "Yes", 
            "time_frame": "8 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02010333"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Hatchtech Pty Ltd", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Hatchtech Pty Ltd", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2013", 
        "study_design": "Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}